{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:32:09Z","timestamp":1773372729909,"version":"3.50.1"},"reference-count":12,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","issue":"spe2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,11]]},"DOI":"10.31744\/einstein_journal\/2026ao1748","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:05:25Z","timestamp":1773335125000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of multiple myeloma in patients with access to novel drugs"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9673-1945","authenticated-orcid":false,"given":"Leonardo Javier","family":"Arcuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0336-2026","authenticated-orcid":false,"given":"Danielle","family":"Ovigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-5062","authenticated-orcid":false,"given":"Cinthya Corr\u00eaa da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-1544","authenticated-orcid":false,"given":"Fernando","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-0696","authenticated-orcid":false,"given":"Ricardo","family":"Helman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5310","authenticated-orcid":false,"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"10","key":"key20260312170523_B1","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers12102885","article-title":"Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020","volume":"12","author":"Bobin","year":"2020","unstructured":"1 Bobin A, Liuu E, Moya N, Gruchet C, Sabirou F, L\u00e9vy A, et al. Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020. Cancers (Basel). 2020;12(10):2885. Review.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"key20260312170523_B2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","unstructured":"2 Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20260312170523_B3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","unstructured":"3 Rosi\u00f1ol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hern\u00e1ndez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337-45.","journal-title":"Blood"},{"issue":"29","key":"key20260312170523_B4","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","unstructured":"4 McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-89.","journal-title":"J Clin Oncol"},{"issue":"7","key":"key20260312170523_B5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","article-title":"Six persistent research misconceptions","volume":"29","author":"Rothman","year":"2014","unstructured":"5 Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29(7):1060-4. Review.","journal-title":"J Gen Intern Med"},{"issue":"15","key":"key20260312170523_B6","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","unstructured":"6 Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. Erratum in: J Clin Oncol. 2005;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve].","journal-title":"J Clin Oncol"},{"issue":"26","key":"key20260312170523_B7","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","unstructured":"7 Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-9.","journal-title":"J Clin Oncol"},{"issue":"8","key":"key20260312170523_B8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","unstructured":"8 Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-66.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20260312170523_B9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","unstructured":"9 Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-96.","journal-title":"Lancet Oncol"},{"issue":"10192","key":"key20260312170523_B10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","unstructured":"10 Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38. Erratum in: Lancet. 2024;404(10455):e3.","journal-title":"Lancet"},{"issue":"5","key":"key20260312170523_B11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","unstructured":"11 Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667-86. Review.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"key20260312170523_B12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","unstructured":"12 Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158. Review.","journal-title":"Blood Cancer J"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:05:28Z","timestamp":1773335128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/outcomes-of-multiple-myeloma-in-patients-with-access-to-novel-drugs\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"journal-issue":{"issue":"spe2","published-print":{"date-parts":[[2026,3,11]]}},"alternative-id":["10.31744\/einstein_journal\/2026AO1748"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026ao1748","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eAO1748"}}